Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical-device maker NuVasive (Nasdaq: NUVA) has earned a respected four-star ranking.

With that in mind, let's take a closer look at NuVasive's business and see what CAPS investors are saying about the stock right now.

NuVasive facts

Headquarters (Founded)

San Diego (1997)

Market Cap

$1.25 billion

Industry

Health-care equipment

Trailing-12-Month Revenue

$493.62 million

Management

Chairman/CEO Alexis Lukianov

COO Keith Valentine

Return on Equity (Average, Past 3 Years)

3.7%

Cash/Debt

$193 million / $230 million

Competitors

Johnson & Johnson (NYSE: JNJ)

Medtronic (NYSE: MDT)

Stryker (NYSE: SYK)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 89% of the 180 members who have rated NuVasive believe the stock will outperform the S&P 500 going forward. These bulls include buffalonate and Hotpicks101.

Just two weeks ago, buffalonate succinctly summed up the bull case for our community: "interesting medical device company showing good growth in the spinal surgery market."

Over the next five years, in fact, NuVasive is expected to grow its bottom line at a brisk rate of 18% annually. That's much faster than gorilla rivals Johnson & Johnson (6.5%), Medtronic (8.3%), and Stryker (10.8%).

CAPS member Hotpicks101 elaborates on the NuVasive bull case:

Wow, so glad I came across this stock. Could this be the new [Intuitive Surgical]? I'm not sure, but what I do know is that this is a company that has repeatedly been beating earnings estimates for the last 3 years. ... Furthermore, it is currently in an unfavorable sector. ... All of which I love. As far as negatives are concerned. Maybe the growth estimates are too high and it may not execute but if history is any indication I just don't see that happening.

What do you think about NuVasive, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson, Stryker, and Intuitive Surgical, as well as creating a diagonal call position in Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Medtronic. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.